Contribute Try STAT+ Today

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to promenade with the official mascot, hang with our short person, catch up on some reading and attempt to beautify the Pharmalot grounds. And what about you? This may be a good time to do some spring cleaning around your castle. You could enjoy the great outdoors and get some exercise. You might also check on vaccination opportunities. Well, whatever you do, have a grand time. But be safe — wear mask. Enjoy, and see you soon …

Johnson & Johnson (JNJ) privately reached out to Covid-19 vaccine rivals to ask them to join an effort to study the risks of blood clots and speak with one voice about safety, but Pfizer (PFE) and Moderna (MRNA) declined, The Wall Street Journal reports. J&J also sought to build an informal alliance to communicate the benefits and risks of the shots and address public concerns about blood-clot cases. Pfizer and Moderna objected because they did not see a need to duplicate efforts of regulators and companies. One company was also concerned their shot could be tarnished by association. Only AstraZeneca agreed.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.